Medical supplies

EcoMedSupply: A Leading Provider Of Environmentally Friendly Medical Supplies, Office Supplies And Foodservice In The United States

EcoMedSupply continues its mission of providing top-notch green supplies that offer high level protection and meet ASTM Level 3 mask standards with one of the highest filtrations on the market.

Protecting the environment is not the business of environmental specialists alone. All hands should be on deck to ensure that the land and its contents are preserved for continued survival and existence. There is no gain in saying that balance is getting harder and harder to achieve, but with organizations like EcoMedSupply, it is now possible to conserve land and make it suitable for habitation.

EcoMedSupply has provided environmentally friendly products, all meeting ASTM standards for high level protection. Founded by Barbara Inwald, MD, EcoMedSupply prides itself on its ability to provide customers with a wide selection of supplies while making them environmentally friendly. While other companies compromise on quality or skimp on catalog size, EcoMedSupply offers thousands of products from hundreds of vendors in an easy-to-use centralized marketplace designed for start-to-finish simplicity and convenience.

EcoMedSupply’s categories of green supplies include medical, dental, personal and skin, veterinary and pet care, office and food. Within the medical supplies category, there are exam room supplies, PPE and staff clothing, office and home care, bed pans and incontinence care, and EMS supplies. , among other articles. The dental supplies category offers supplies for all parts of the dental office, including toothbrushes and floss, HVEs, saliva ejectors, prophylaxis angles, micro-applicators, syringe tips A / W, arc trays, impression syringes, and examination room paper products.

Spas, wellness centers, and homes in need of green skin care supplies will find the best products in EcoMedSupply’s personal and skin care supplies category. Veterinarians and pets are also included in EcoMedSupply’s scope to provide environmentally friendly supplies. EcoMedSupply is undoubtedly leading the way in the conservation of natural life with its categories of food and office supplies.

In addition to this, EcoMedSupply offers an informative section on its website, educating visitors about the environmental impact on healthcare and why concerted efforts should be made to ensure that only environmentally friendly products are made and used around the world today. To join the Ensuring the Earth is Safe for Home and for Posterity course, please visit and purchase one of the very affordable and environmentally friendly products available.

Media contact
Company Name: EcoMedSupply
Contact: Barbara inwald
E-mail: Send an email
Call: 415-250-5393
Country: United States

read more
Generic drugs

Generic drugs provide information to doctors, so why is Health Canada promoting pharmaceutical brand names?

Generic drug names are often long, but they can tell doctors what type of drug it is and how it works. But it is the brand names that appear first and most prominently in Health Canada documents.

Brand names are widely used when we want to refer to a specific product – an Apple computer, a Tesla car. Sometimes brand names are used so widely that they take over – we ask for a Kleenex instead of a tissue.

Drugs have two names. The brand name is the one chosen by the company that manufactures it and that company is the only one authorized to use the name. (The name proposed by the company is being reviewed by Health Canada.) Brand names are almost always short and catchy so that physicians will remember them.

Generic names are assigned globally by the World Health Organization in collaboration with national naming authorities. These names are often long, but part of the reason for this is that they tell doctors about the pharmacological properties and / or chemical structure of the drug.

The generic name of the US $ 2 million per patient new drug for spinal muscular atrophy is onasemnogene abeparvovec. The brand name is Zolgensma. Which one will physicians (and patients) retain and use? The answer is obvious.

One of the associate editors of the Canadian Medical Association Journal notes that “some brand names are created to be reassuring or promising – so-called ‘benefit-oriented’ names such as Paxil, Celebrex, and Gluconorm – while they should in fact be prescribed with great care and taking into account the potential effects of the drug on each patient.

Is using brand names the right way to talk about prescription drugs? Apparently, Health Canada thinks so. Do you want information on safety issues with a medicine? On the Canadian recall site, you will see the brand name in CAPITALS and the generic name in lower case and in parentheses.

Want to see if there is a shortage of the drug your doctor just prescribed for you? Go to Drug Shortages Canada and you will find the brand names of the drugs, again in all caps.

If you want to know why Health Canada approved a particular drug, the Basis of Approval Summary document will help you understand. But again, the brand name is the most important, and again it’s in all caps.

What’s in a name?

In medical school, students learn to use generic names. Medical journals require authors to use generic names in the articles they write. Does the name used by doctors matter? The answer is yes.

When Australian anesthesiologists and doctors trained to be anesthesiologists at two university hospitals were given the brand names of the drugs, they could only correctly identify the therapeutic group from which the drug came in just over half of the cases. Without knowing which therapeutic group the drug was from, doctors could have accidentally used another drug from the same group or they could have used the drug incorrectly.

The more money doctors received from drug companies in the form of meals, travel arrangements, and property royalties, the less likely they were to prescribe by generic name. Seeing pharmaceutical company sales representatives more frequently is associated with increased prescriptions for brand name products, resulting in more expensive prescriptions. Sales representatives also typically omit important information about the safety of the drugs they are promoting. Therefore, besides more expensive prescriptions, they can also be more likely to harm patients.

Brand names, drug regulation (the domain of Health Canada) and drug promotion came together particularly blatantly in the case of buprenorphine-naloxone, the brand name Suboxone, an opioid drug used to treat addiction. opioids.

Even though generic formulations of the drug have been available in Canada since 2013 (and even earlier in the United States), the drug is widely referred to by its brand name, including in the media, by policymakers, and by physicians.

Brand education

This happened in particular through the promotion of an “educational” program developed and implemented by Indivior, the company which owns the rights to Suboxone. In some provinces, completing this branded program is a prerequisite for prescribing buprenorphine-naloxone. The same strategy was used for a related injectable form of buprenorphine, also owned by Indivior.

This use of the branded program is the case even though there are already some very good accredited, non-industry educational programs to teach proper opioid addiction care and prescriptions to doctors, nurses and pharmacists.

The inclusion of the brand name in the title of this program is against recommended practices and accreditation standards for Canadian medical education programs.

Yet the brand-name program is fully endorsed by Health Canada through that agency’s review and approval of the Suboxone Product Monograph. This document, which describes the nature of the drug and its approved uses in Canada, includes a description of the requirement to participate in the branded “training program”.

As has been documented in the United States, Indivior and its parent company Reckitt Benckiser have engaged in various unscrupulous practices to promote their multibillion-dollar line of buprenorphine products – ultimately paying some of the largest fines in the world. pharmaceutical history of the United States. From this perspective, a branded “educational” program appears to be yet another vehicle for brand promotion, and one in which Health Canada is directly involved.

When doctors use brand names, they may be less knowledgeable about the medications they are prescribing, their prescriptions cost more, and patients may be more likely to suffer from side effects. When Health Canada prioritizes brand names over generic names, it is actively contributing to all of these issues.

Health Canada should know better and do better.

In 2018-2021, Joel Lexchin received payments for writing a dissertation in a drug side effects action for Michael F. Smith, lawyer, and a second dissertation on the role of promotion in generating orders for Goodmans LLP and Canadian Institutes of Health Research for a presentation at a workshop on conflicts of interest in clinical practice guidelines. He is currently a member of research groups that receive funding from the Canadian Institutes of Health Research and the Australian National Health and Medical Research Council. He is a member of the Foundation Board of Health Action International and the Board of Canadian Doctors for Medicare. It receives royalties from the University of Toronto Press and James Lorimer & Co. Ltd. for the books he wrote.

Abhimanyu Sud has received funding or has been consulted by the Canadian Institutes of Health Research, Health Canada, the Association of Faculties of Medicine of Canada, the University of Toronto, the Center for Effective Practice and the Mississauga-Halton Local Health Integration Network for research and medical education related to opioid use and drug policy.

read more
Medical products

FDA Approves Two Oral COVID-19 Drugs – Medical Products Supply Chain Weekly Review | Alston & Bird

Last week, the FDA cleared oral antivirals from Pfizer and Merck for the treatment of COVID-19. The Biden-Harris administration released the trucking action plan. The CDC approved the ACIP preference recommendation for the Pfizer-BioNTech and Moderna vaccine boosts. The new recommended Tris vaccine buffer leads to greater stability and does not require dilution. Please see details of these and other supply chain developments below:

  • On December 15, the FDA approved Eagle Pharmaceuticals’ Abbreviated New Drug Application (ANDA) for injection of vasopressin (20 units / ml in multidose vials), a product that has grown in demand during the COVID-pandemic. 19. The FDA said that this approval – the first approval from an ANDA for this product – represents the agency’s commitment “to facilitate access to medical products to help meet the critical needs of the American public.”
  • On December 16, the Authority released its Trucking Action Plan to help reduce supply chain disruption as part of initiatives encouraged by the Chain Disruption Task Force. supply. Globally, the plan aims to implement measures to reduce barriers to the issuance of commercial driver’s licenses (CDLs); accelerate the learning of trucking; recruit veterans, especially those with previous trucking experience, into the industry; and schedule listening sessions with the current workforce to implement improvement strategies. In order to promote immediate implementation, the plan also includes specific actions for 30, 60 and 90 days to implement the objectives of the plan.
  • On December 16, the FDA approved the use of Tris buffer for the manufacture of Pfizer-BioNTech’s Comirnaty COVID-19 vaccine. This new formulation offers two key advantages to vaccinators: (1) it increases the stability of the vaccine longer at refrigerated temperatures; and (2) it does not require dilution by the supplier before use.
  • On December 16, the CDC approved the Advisory Committee on Immunization Practices (ACIP) recommendations that the Pfizer-BioNTech and Moderna vaccines are preferred for booster use over the Johnson & Johnson vaccine. ACIP met earlier today and based its decision on data including a review of efficacy and adverse events.
  • On December 17, the FDA announced that it was considering a program that would impose sterilization changes to the master file pilot program for 510 (k) approved medical devices. The change applies to the established Category B or to new sterilization methods. In addition to manufacturers in the innovation challenge, current 510 (k) holders can also participate in two previous programs where the FDA (1) has challenged manufacturers to develop new ways to develop alternatives to it. ethylene oxide; and (2) reduce emissions of ethylene oxide. If changes are made to sterilization methods when ethylene oxide is used, participants can now refer to their master files instead of submitting a new 510 (k).
  • On December 20, Moderna announced that it was continuing to advance clinical trials to develop an omicron-specific vaccine for use as a booster. He also noted that the antibodies from his 50mcg and 100mcg booster doses demonstrated a 37- and 83-fold increase in antibody levels. Clinical trials of vaccines targeting both omicron and delta are underway.
  • On December 21, the Center for Devices and Radiological Health (CDRH) released a plan for how the CDRH intends to manage reviewer workload in 2022 based on the increase in the total number of submissions. In 2021, the CDRH saw an increase in medical device submissions for approval through the traditional processes, namely the PMA, 510 (k) and Q-sub processes, which it addressed through the implementation of new approaches to review, including triage of cases, reallocation of staff and resources to COVID-19 products, use of contractors and overtime. Despite these approaches, some issues related to meeting review deadlines still need to be resolved. For devices other than in vitro diagnostics, the CDRH expects to be able to meet the review deadlines of the Medical Device User Fee Agreement (MDUFA) in 2022 despite the influx of medical products subject to review. For in vitro diagnostic products, the CDRH will also try to meet the deadlines promised by the MDUFA. Non-COVID products that were not prioritized during the pandemic will require extended review times. In addition, the pre-submission request program will be reinstated as of January 1, 2022.
  • On December 22, the FDA cleared Pfizer’s oral antiviral drug, Paxlovid, for the treatment of mild to moderate COVID-19 in adults and children 12 years of age or older (weighing 40 kg or more). This is the first oral antiviral treatment for COVID-19 to receive emergency use authorization. The clearance was based on data from the EPIC-HR trial, which demonstrated that Paxlovid significantly reduced hospitalizations and deaths from any cause in the study population compared to those randomized to receive a placebo. Paxlovid is a combination of nirmatrelvir and ritonavir – the former inhibits the replication of SARS-CoV-2 and the latter slows down the breakdown of nirmatrelvir in the body. The FDA will continue to monitor clinical trial data for the safety and effectiveness of the drug.
  • On December 23, the FDA cleared Merck’s oral antiviral drug, molnupiravir, for the treatment of mild to moderate COVID-19 in adults at high risk of progression to severe COVID-19 and for whom options for Alternative treatment to COVID-19 is not available. accessible or clinically appropriate.

[View source.]

read more
Prescription drugs

Florida to become the first state to import prescription drugs from Canada

Plans to import cheaper prescription drugs from Canada have been in the works for years. In Florida, it could finally happen sooner than many realize – perhaps as early as early next year.

Florida Health Care Administration Secretary Simone Marsiller recently told a state Senate panel, “Hopefully we can start importing in the first quarter of the new year.

The fact that, while they differ in everything else, President Joe Biden and Governor Ron DeSantis both support her.

“If you have drugs in Canada, the same drug costs 25 percent of what it costs here. We want Floridians to be able to share those discounts,” DeSantis said.

A RAND study looked at drug prices in nearly 40 countries and found that the United States pays more than all prescription drugs. Average prices have risen by about 250% in the United States or, as President Biden recently noted, “about two to three times what other countries pay.”

In the United States, insurance companies cover most of the cost of drugs for those who are insured. But those without coverage and those with insurance that doesn’t cover their particular medications burn themselves or go without.

In Canada, prescription drugs are much cheaper because the Canadian government regulates and controls the prices. So the idea is to help Americans take advantage of Canada’s price controls.

As you might expect, the pharmaceutical lobby opposes plans to import prescription drugs from Canada. He ran advertisements questioning the safety of using drugs imported from other countries – an advertisement even stating: “Too many have already died from counterfeit drugs; are you willing to take that risk? “

PREVIOUS: Advertising campaign claims imported drugs are risky for Floridians

But Governor Ron DeSantis says we can trust Canada – and Congress agrees. He passed a law allowing commercial imports of drugs from Canada in 2003. Sixteen years later, Florida was one of the first states to begin the process.

The state has spent the past two years putting the system in place, which the governor says will keep it safe.

“This program only applies if we show that we are providing drugs that are safe and cheaper than what we already have,” said Governor DeSantis.

The final step is FDA clearance, and President Biden has already ordered the FDA to get to work. As soon as the FDA gives the green light, Florida plans to take action.

PREVIOUS: Florida drug import plan moves forward

Life Science Logistics in Lakeland is ready at this time. Its warehouses would start filling up with boxes and bottles of pills – all prescription drugs from Canada.

“We’re ready to start importing in 90 days,” a company spokesperson told FOX 13.

The state has not defined or announced certain details, such as which drugs will come first. State officials have suggested they could start with drugs to treat diabetes, hepatitis, COPD and / or HIV / AIDS.

They will likely start with a small number of drugs for those with Medicaid, then for others with public insurance. Further expansion would be based on the success of the program as well as demand.

There are some wrinkles in the plane that need to be addressed. The pharmaceutical industry is challenging it in court. And supplies can also be a problem, as Canada cannot supply its own citizens while having enough for the United States, or even all of Florida, for that matter. Shipments should be considered “surplus” or “surplus” in the Canadian market.

But after years of planning, Florida could overcome these hurdles in 2022, triggering big changes in where we get our drugs and how much we pay for them.

read more
Prescription drugs

Counterfeit prescription drugs and illicit cigarettes worth hundreds of thousands of pounds seized in Orford raid

TWO men have been arrested after police seized hundreds of thousands of pounds of counterfeit prescription drugs and illicit cigarettes following a raid in Orford, Warrington.

Over the past several months, agents from the Warrington Problem-Solving Team have conducted a detailed investigation into the illegal supply of prescription drugs in the town.

On Tuesday, December 21, the team conducted a warrant at an address in Orford where they recovered thousands of counterfeit prescription drugs, around £ 200,000 of counterfeit cigarettes and tobacco and a large amount of stolen wine and spirits .

Two local men, aged 67 and 31, were also arrested at the address on suspicion of money laundering and receiving stolen property.

The couple have since been released under investigation pending further investigation.

Sergeant Anthony Sullivan of the Warrington Problem Solving Team said: “This warrant is part of our ongoing investigation into the supply of illegal drugs.

“Illegal drugs have no place in our city; they are ruining the lives of some of the most vulnerable people in our community, while lining the pockets of shameless criminals.

“I want to reassure the public that we are doing everything we can to crack down on this type of activity.

“However, we cannot do our job without the help of the public and cannot repeat the message enough that you are essential in helping your community by reporting illegal activity to us.

“If anyone has any information about illegal drug activity or any other criminal activity taking place in your community, they should report it to Cheshire Police on 101 or .

“Information may also be reported anonymously, via Crimestoppers, on 0800 555 111.”

read more
Prescription drugs

The future of the safe harbor for prescription drugs remains uncertain

In November 2020, four months after the Trump administration issued a series of executive orders reiterating its policy goals on reducing costs for consumers of prescription drugs and leading the Department of Health and Human Services, Office of the Inspector General (“HHS-OIG”) to implement these policy objectives, the HHS-OIG has issued a Final rule to amend certain provisions of the Safe Harbor regulation under the Federal Anti-Recoil Act (“AKS”). The final rule included three key provisions:

  1. Removal Safe Harbor protection for manufacturer discounts paid directly or indirectly through a Pharmacy Benefits Manager (“PBM”) to Medicare Part D or Medicare Advantage plans (the “Discount Rule”). “);
  2. Creation of a new safe harbor to protect point-of-sale (“POS”) price reductions paid by manufacturers to Medicare Part D plans, Medicare Advantage plans and Medicaid managed care organizations (“MCO”); and
  3. Creation of a new safe harbor to protect the fair market value (FMV) service fees paid to PBMs by manufacturers.

The final rule imposed an effective date of January 1, 2022 for the discount rule. However, in January 2021, two months after the final rule was issued and in a lawsuit by the Pharmaceutical Care Management Association challenging the surrender rule, the Biden administration agreed to postpone the entry date. in force of the discount rule on January 1, 2023, as reflected in a Order by the United States District Court for the District of Columbia.

In the meantime, however, Congress passed the Law on investment in infrastructure and employment (the “Infrastructure Act”). This law, signed by President Biden on November 15, 2021, further delayed the implementation of the discount rule until January 2026. Thus, the rule, which many believed would be removed as part of the payment of the cost of the infrastructure bill, was still alive, if only delayed until the middle of the next presidential term.

Then, on November 19, 2021, the House of Representatives adopted the Rebuild Better Act (“BBBA”), which included the last nail in the coffin of the ruler. Section 139301 of this bill stated that the HHS-OIG “shall not implement, administer or enforce” any of the provisions of the rule. This was the total repeal that had been provided for in the previous law.

The bill went to the Senate before Thanksgiving and was to go through a reconciliation process that is exempt from Senate filibuster rules and would only have required all 50 Democratic and Independent Senators to vote for, the Deputy Speaker Kamala Harris playing the tiebreaker role. 51st vote in favor of the bill. However, Senator Joe Manchin (D – W. Va.) Recently announced his opposition to the bill, and his vote could prevent the bill from being passed. If the BBBA is not passed by the Senate, its ban on implementing the final rule will fail with it, and unless any further action is taken, the discount rule will take effect in January 2026.

As a result, it is not clear until the Senate took action in January whether PBMs, MCOs, Part D plans and Medicare Advantage plans will need to worry about these changes to the anti-rollback provisions. . If the Senate does not pass the bill, then all of these entities should begin reviewing their policies and procedures over the next four years in preparation for the rule coming into force.

Reed Smith will continue to monitor developments related to the discount rule and its impact on the industry.

read more
Medical supplies

Fidelity Securities Limited donates medical supplies to police hospital

Fidelity Securities Limited, a subsidiary of Fidelity Bank Ghana Limited, donated medical supplies to the pediatric ward of the Ghana Police Hospital in Accra.

The supplies, including a CPAP machine, infuser, x-ray viewer, pulse oximeter, digital thermometer, pediatric ambubag, industrial nebulizer, oxygen concentrator (5L) and oxygen flow meter will help to provide health care to the children on the unit.

Presenting the articles at Ghana Police Hospital, Edward Opare-Donkor, Board Member of Fidelity Securities Limited, said: “Fidelity Securities Limited is more than grateful for being able to fulfill its civic duty in helping to save the lives of children across the country who visit the facility. Indeed, we are committed to supporting the government in providing the best health care to the people of Ghana. “

Mr. Opare-Donkor noted that this was only the beginning of Fidelity Securities Limited’s relationship with the Ghana Police Hospital and he encouraged the Ghana Police Hospital to continue its selfless sacrifice to the nation.

Receiving the articles on behalf of Ghana Police Hospital, Dr Ebenezer Ewusi-Emmim, Medical Director of Ghana Police Hospital, said: “We appreciate Fidelity Securities Limited for supporting us with these valuable medical supplies at this very critical time.

“We will use these supplies wisely while encouraging them and other commercial institutions to continue to support us in delivering first-class health services to the people of this country.”

FSL’s support to the Ghana Police Hospital is a demonstration of its commitment to the general well-being of Ghanaians through its social impact initiatives.

read more
Medical supplies

COVID -19: Big Caps Micro Credit donates PPE and medical supplies to Agona Swedru municipal hospital

As the holiday season begins, many hospitals and health facilities in the central region have stepped up efforts to vaccinate and educate people about the need to minimize the spread of the COVID-19 virus.

The Central Region, for example, is seeking to reach a vaccination target of one million seven hundred thousand and health officials have stepped up efforts to ensure that the target is met.

Dr Julius Agbeeku, Acting Medical Superintendent of Agona Swedru Government Hospital, said that at a time when many seemed to have forgotten about the existence of the COVID-19 virus, there was no longer a need to step up education and strengthen immunization.

The Central region recorded its first case of COVID-19 on April 8, 2020. As of December 7, 4,907 cases have been recorded cumulatively since the start of the pandemic. 98% of recorded cases, according to the GHS, have fully recovered from COVID-19. At the last count, the total number of deaths stood at 31.

Speaking at a ceremony to receive PPE and other medical supplies worth GHG 36,000 from Big Cap Micro Credit, Dr Agbeeku called on residents to protect themselves this Christmas time.

He says: “Because we’ve seen waves upon waves, pandemic efforts seem to have waned a bit. So, for them to remember that we still need to fight this pandemic, and to help with this donation, we are eternally grateful to them.

Ag. Medical Superintendent, Agona Swedru Government Hospital, Dr Julius Agbeeku

The acting medical superintendent of the government hospital of Agona Swedru also debunked the notion of some people against vaccination. He explained that the problems some people have with vaccination were unfounded and it was necessary to dismiss such thoughts.

“We make efforts to educate and sensitize people so that they reason with us in order to be vaccinated. Some of the things they say you just don’t get the basis for.

There are so many vaccines available that we can immunize a lot of people, ”he said.

He thanked BIG CAP Micro Credit for such a donation which would help fight against the virus. Management, he says, will increase its risk communication as the waves of the pandemic keep rising.

COVID -19: Big Caps Micro Credit donates PPE and medical supplies to Agona Swedru municipal hospital

Big Cap Micro Credit CEO Firdaus Mubarak Yusif explained that the donation worth 36,000 is part of their corporate social responsibility by supporting the public in the fight against the virus.

The articles, he says, were strategic articles that will eradicate many of the problems that exist in the region. He believes that if the items are used wisely, there will be many challenges.

COVID -19: Big Caps Micro Credit donates PPE and medical supplies to Agona Swedru municipal hospital
CEO of Big Cap Micro Crédit, Firdaus Mubarak Yusif

” I protect myself ; you don’t protect yourself; you have the virus. You protect yourself; I don’t protect myself; I catch the virus. As an organization, we would contribute significantly, not only to support the fight against the COVID-19 virus, but also to address the challenges of our rural health sector.

Agona West MP Cynthia Mamle Morrison expressed her appreciation for the gesture and called on the general public and businesses to support healthcare facilities in these difficult times.

COVID -19: Big Caps Micro Credit donates PPE and medical supplies to Agona Swedru municipal hospital
MP, Agona West, Cynthia Mamle Morrison

She added that at the start of the Christmas season, many people would be left out of the celebration because they are not taken care of.

“During this Christmas season, we pray that legal entities will reach out not only to hospitals, but also to the needy, the elderly, the sick and other vulnerable groups in our society. I’m telling you that without a gift some people won’t celebrate Christmas, ”she said.

read more
Generic drugs

Generic Drugs Market in United States, By Type, By Application, By Drug Delivery Method, By Form, By Source, By Distribution Channel, By Region, Competition, Forecast And Opportunity, 2026

Generic Drugs Market in United States, By Type (Small Molecule Generics Vs Biosimilars), By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Infectious Diseases, Others), By Mode Of Drug Administration (Oral, Topical, parenteral, other), by form (tablet, capsule, injection, other), by source (in-house or contract manufacturing organizations), by distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, others), by region, competition, forecast and opportunities, 2026

New York, December 23, 2021 (GLOBE NEWSWIRE) – announces the publication of the report “Generic Drugs Market in United States, By Type, By Application, By Drug Administration, By Form, By Source, by distribution Channel, by region, competition, forecast and opportunities, 2026 “-

The US generic drug market was valued at USD 70.78 billion in 2020 and is expected to grow at a CAGR of 9.43% during the forecast period and may reach a market value of USD 126.74 billion by 2026. Factors such as the profitable nature of generic drugs and increasing demand from developing economies are primarily responsible for this estimate of the futuristic growth of the US generic drug market over the next five years. Generic drugs do not require extensive research and development like prescription drugs and patented drugs. Market players and research institutes invest heavily in pharmaceutical patents. In addition, FDA approvals for generic drugs are not required because the generic drugs contain the same composition as the previously patented drug and thus support the growth of the US generic drug market over the next five years. The healthcare industry in the United States, in terms of generic drugs, has gone from an 80% growth in 2020 to a previous growth of 20% in 2015.
Increasing exports of generic drugs to developing economies like Kenya, India etc. also confirms the growth of the US generic drug market in the next five years.
The generic drugs market in the United States is segmented on the basis of drug type, mode of administration, form, source of manufacture, application, company, and regional distribution. Based on type, the market can be divided into generics and small molecule biosimilars.

Small Molecule Generics are expected to achieve the largest market revenue shares and dominate the market segment over the next five years due to their simpler and easier manufacturing processes. Manufacturers of generic drugs when producing generics with small molecules are required to prove that the end product contains chemical compounds identical to those of the patented drug.

With similar pharmacokinetic functions and properties, the generic small molecule is accepted. In addition, the demand for cost-effective generic drugs is expected to further support the growth of the US generic drug market over the next five years.
Based on the applications, the market may be fragmented into cardiovascular disease, diabetes, neurology, oncology, infectious disease, and others. Cardiovascular disease is expected to dominate the market segment while recording the largest market revenue shares over the next five years on account of growing cardiovascular disease cases in the United States.

Additionally, the increased demand for the treatment and extended drug regimens is driving the growth of the cardiovascular disease sub-segment while supporting the growth of the generic drug market in the United States over the next five years. Increased pharmaceutical research and development for the oncologic disease is expected to drive the growth of the oncology sub-segment and drive the growth of the US generic drug market over the next five years.
Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sandoz US, Endo Pharmaceuticals Inc., Aurobindo Pharma USA, Inc., Abbott Laboratories Inc., Eli Lilly and Company, Sun Pharma Inc., Lupine Pharmaceuticals, Inc. and Zydus Pharmaceutical USA Inc. is among the major market players in United States leading the growth of the generic drug market.

Years considered for this report:

Historical years: 2016-2019
Baseline year: 2020
Estimated year: 2021
Forecast period: 2022-2026

Goal of the study:

• To analyze the historical growth in the market size of the generic drugs market in the United States from 2016 to 2020.
• Estimate and forecast the US generic drugs market size from 2021 to 2026 and the growth rate to 2026.
• To categorize and forecast the United States generic drug market on the basis of drug type, application, drug administration route, form, source, distribution channel, competitive landscape, and regional distribution.
• Identify the dominant region or segment in the generic drug market in the United States.
• Identify the drivers and challenges of the US generic drug market.
• Examine competitive developments such as expansions, new product launches, mergers and acquisitions, etc., in the US generic drug market.
• Identify and analyze the profile of the main players operating in the US generic drug market.
• Identify the main sustainable strategies adopted by the players in the generic drugs market in the United States.
The analyst performed both primary and secondary research exhaustive for this study. Initially, the analyst found a list of manufacturers around the world.

Subsequently, the analyst conducted primary research surveys of the identified companies. During the interviews, respondents were also asked about their competitors.

Using this technique, the analyst could include manufacturers who could not be identified due to the limitations of secondary research. The analyst looked at manufacturers, distribution channels and the presence of all major players across the globe.
The analyst calculated the size of the generic drugs market in the United States using a bottom-up approach, in which data from various end-user segments was recorded and forecast for years to come. The analyst obtained these values ​​from industry experts and company representatives and validated them externally by analyzing historical data for these types of products and applications to arrive at an appropriate overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations, and financial reports were also investigated by the analyst.

Key target audience:

• Manufacturers, suppliers, distributors and other stakeholders of generic drugs
• Government bodies such as regulatory authorities and policy makers
• Organizations, forums and alliances related to generic drugs
• Market research and consulting firms
The study is useful in providing answers to several critical questions that are important to industry players such as manufacturers, suppliers, partners, end users, etc., in addition to enabling them to develop investment strategies and capitalize on market opportunities.

Scope of the report:

In this report, the United States Generic Drugs Market has been segmented into the following categories in addition to industry trends which have also been detailed below:
• Generic Drugs Market in United States, by Type:
o Generic Small Molecule
o Biosimilars
• United States Generic Drugs Market, By Application:
o Cardiovascular diseases
o Diabetes
o Neurology
o Oncology
o Infectious diseases
o Others
• Generic drug market in the United States, by drug administration method:
o Oral
o Parenteral
o Topical
o Others
• Generic Drugs Market in United States, by Form:
o Capsule
o Injection
o Others
• Generic drugs in the United States, by source:
o In-house manufacturing
o Contract manufacturing organizations
• Generic drug market in the United States, by distribution channel:
o Retail pharmacies
o Online pharmacies
o Hospital pharmacies
o Others
• Generic drug market in United States, by region:
o South
o Midwest
o West
o North East

Competitive landscape

Company Profiles: Detailed analysis of the major companies present in the global generic drugs market.

Customizations available:

With the market data provided, we offer customizations based on the specific needs of a business. The following customization options are available for the report:

Company Info

• Detailed analysis and profiling of additional market players (up to five).
Read the full report:

About Reportlinker
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.


CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
read more
Generic drugs

Generic Inhalation and Nasal Spray Market $ 6.87 Billion by Indication, Age Group, Class, Route, Distribution Channel and Region

Dublin, December 23, 2021 (GLOBE NEWSWIRE) – The ‘Generic Inhalation Drugs and Nasal Sprays Market Research Report by Indication, Age Group, Class, Route, Distribution Channel and Region – Global Forecast to 2026 – Cumulative impact of COVID- Report 19 “has been added to offer.

The global generic inhalation and nasal spray market size was estimated to be USD 6,392.52 million in 2020, is expected to reach USD 6,879.55 million in 2021, and is expected to grow at a CAGR of 7.95% to reach 10,119 , 95 million USD by 2026.

Market statistics
The report provides market size and forecast in five major currencies: USD, EUR GBP, JPY, and AUD. It helps organizational leaders make better decisions when currency data is readily available. In this report, the years 2018 and 2019 are considered as historical years, 2020 as the base year, 2021 as the estimated year and the years 2022 to 2026 are considered as the forecast period.

Market segmentation and coverage

This research report categorizes Generic Inhalation Drugs and Nasal Sprays to forecast revenue and analyze trends in each of the following submarkets:

  • Based on the indication, the market has been investigated for allergic rhinitis, asthma and COPD.

  • Based on age group, the market has been researched among adults, children 2-5 years old, and children 6-12 years old.

  • Based on the class, the market has been studied for allergy blockers, anticholinergics, antihistamines, decongestants, mast cell inhibitors, and nasal steroids.

  • Based on Route, the market has been investigated for inhalation, nasal spray, and tropical lotion.

  • Based on the distribution channel, the market has been studied in hospital medical stores, online pharmacies and retail pharmacies.

  • Based on the region, the market has been studied in the Americas, Asia-Pacific and Europe, Middle East and Africa. The Americas are studied in more detail in Argentina, Brazil, Canada, Mexico and the United States. The United States is studied in more detail in California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. Asia-Pacific is further explored in Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, the Middle East and Africa are studied in more detail in France, Germany, Italy, the Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates and United Kingdom.

Companies mentioned

  • Allergan plc

  • Altaire Pharmaceuticals inc.

  • Beximco Pharmaceuticals Ltd.

  • Catalent Pharma Solutions

  • Cipla Limited

  • Hikma Pharmaceuticals PLC

  • Mylan NV

  • Navajo Manufacturing Company Inc.

  • Pharmaceutical company Nephron

  • Perrigo Company plc

  • Preferred Pharmaceuticals Inc.

  • Sandoz International GmbH

  • Sheffield Pharmaceuticals LLC

  • Sun Pharmaceutical Industries Ltd.

  • Teva Pharmaceutical Industries Ltd.

Cumulative impact of COVID-19
COVID-19 is an incomparable global public health emergency that has affected nearly all industries, and the long-term effects are expected to impact the growth of the industry during the forecast period. The analyst’s ongoing research is amplifying their research framework to ensure the inclusion of the underlying issues of COVID-19 and potential avenues to follow. The report provides insights on COVID-19 given changes in consumer behavior and demand, purchasing patterns, supply chain diversion, dynamics of current market forces, and significant government interventions. . The updated study provides information, analysis, estimates and forecasts, considering the impact of COVID-19 on the market.

Competitive strategic window
The Competitive Strategy Window analyzes the competitive landscape in terms of markets, applications and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for suppliers to adopt successive strategies of merger and acquisition, geographic expansion, research and development, and new product introduction strategies to continue the expansion and growth of the business during a forecast period.

FPNV positioning matrix
The FPNV Positioning Matrix assesses and ranks vendors in the Generic Inhalation and Nasal Spray market based on business strategy (company growth, industry coverage, financial viability, and channel support) and product satisfaction (value for money, ease of use, product features) and customer support) which helps businesses make better decisions and better understand the competitive landscape.

Market share analysis
The market share analysis offers the analysis of the suppliers considering their contribution to the overall market. It provides the idea of ​​its revenue generation in the overall market compared to other space providers. It provides insight into the performance of vendors in terms of revenue generation and customer base compared to others. Knowing the market share gives an idea of ​​the size and competitiveness of the suppliers for the base year. It reveals the characteristics of the market in terms of traits of accumulation, fragmentation, dominance and fusion.

Competitive scenario
The competitive scenario provides a outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section delivers valuable insights at different stages while staying up to date with the business and engaging stakeholders in the economic debate. The competitive scenario represents press releases or news from companies categorized as M&A, Agreement, Collaboration and Partnership, New Product Launch and Improvement, Investment and Funding, and Reward, Recognition and Expansion. All the news gathered helps the supplier understand the market gaps and the strengths and weaknesses of competitors, thus providing information to improve products and services.

Main topics covered:

1. Preface
1.1. Objectives of the study
1.2. Market segmentation and coverage
1.3. Years taken into account for the study
1.4. Currency and price
1.5. Language
1.6. Limits
1.7. Hypotheses
1.8. Stakeholders

2. Research methodology

3. Executive summary

4. Market overview
4.1. introduction
4.2. Cumulative impact of COVID-19

5. Market dynamics
5.1. introduction
5.2. Conductors
5.2.1. Low cost associated with generic prescription drugs
5.2.2. Increased prevalence of asthma and COPD disorders
5.2.3. High cost of health care in developed regions
5.3. Constraints
5.3.1. Strict regulations for generic drugs
5.4. Opportunities
5.4.1. Successful drug patents expire and FDA approvals increased
5.4.2. Trend towards generic drugs in developed countries due to rising cost of health care
5.5. Challenges
5.5.1. Pressure on prices due to the presence of several players in the segment

6. Generic Inhalation and Nasal Sprays Market, by Indication
6.1. introduction
6.2. Allergic rhinitis
6.3. Asthma
6.4. COPD

7. Generic Inhalation Nasal Spray Drugs Market, By Age Group
7.1. introduction
7.2. Adults
7.3. Children 2 to 5
7.4. Children 6 to 12

8. Generic Inhalation and Nasal Spray Drugs Market, By Class
8.1. introduction
8.2. Allergy blocker
8.3. Anticholinergic
8.4. Antihistamine
8.5. decongestant
8.6. Mast cell inhibitor
8.7. Nasal steroid

9. Generic inhalation and nasal sprays market, by road
9.1. introduction
9.2. Inhalation
9.3. Nasal spray
9.4. Tropical Lotion

10. Generic inhalation and nasal sprays market, by distribution channel
10.1. introduction
10.2. Hospital medical store
10.3. Online pharmacy
10.4. Retail pharmacy

11. America Generic Inhalation and Nasal Spray Market

12. Asia-Pacific Generic Inhalation and Nasal Spray Market

13. Europe, Middle East & Africa Generic Inhalation Drugs and Nasal Sprays Market

14. Competitive landscape
14.1. FPNV positioning matrix
14.1.1. Quadrants
14.1.2. Business strategy
14.1.3. Product satisfaction
14.2. Market ranking analysis
14.3. Market share analysis, by key player
14.4. Competitive scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, collaboration and partnership
14.4.3. New product launch and improvement
14.4.4. Investment and financing
14.4.5. Awards, recognition and expansion

15. Company usability profiles

For more information on this report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
read more
1 2 3 4 5 10
Page 3 of 10